The global Cholangiocarcinoma Market Growth Accelerated by Increasing Prevalence
Cholangiocarcinoma is a rare and aggressive cancer that forms in the bile ducts. The tumor is difficult to treat and has poor prognosis. Early diagnosis of cholangiocarcinoma is challenging as symptoms are vague in early stages. Advances in diagnostic imaging techniques aid in accurate diagnosis. Growing geriatric population and rising risk factors such as primary sclerosing cholangitis are contributing to the increasing prevalence of cholangiocarcinoma.
The global Cholangiocarcinoma Market is estimated to be
valued at US$ 7,275.7 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over
the forecast period 2023 to 2030, as highlighted in a new report published by
Coherent Market Insights.
Market key trends
Increasing prevalence of cholangiocarcinoma due to aging population and
environmental factors is one of the major trends driving the growth of the
market. It has been reported that more than 80% of cholangiocarcinoma patients
are above 55 years of age. Furthermore, industrial chemicals and alcoholic
beverages have been found to increase the risk of bile duct cancer. In
developing countries undergoing industrialization and urbanization, the number
of risk factors like contamination of drinking water sources are on the rise.
This is expected to contribute significantly to the growing prevalence of
cholangiocarcinoma globally over the forecast period. Development of biomarkers
for early diagnosis and treatment will further accelerate the market growth in
coming years.
Segment Analysis
The global cholangiocarcinoma
market is dominated by the intrahepatic cholangiocarcinoma sub-segment due
to the high prevalence rate of the disease arising from intrahepatic bile
ducts. Factors such as rising incidences of liver diseases, obesity etc are
contributing to the high prevalence of intrahepatic cholangiocarcinoma which
forms 60-70% of all cholangiocarcinoma cases globally.
Key Takeaways
The global Cholangiocarcinoma Market is estimated to be valued at US$ 7,275.7
Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period
2023 to 2030.
Key players:
Key players operating in the cholangiocarcinoma market are Johnson & Johnson Services, Inc., Cooper Companies Inc., Lifecell Corporation (Allergan Plc), W. L. Gore & Associates, Inc., Maquet Holding B.V. & Co. KG, Becton, Dickinson and Company, Medtronic Plc, Cook Medical Inc., Baxter International Inc., and B. Braun Melsungen AG.
Comments
Post a Comment